Elecsys anti sars cov n

Blood samples from the entire study population of 975 individuals were collected approximately 30 days after injection of the second vaccine dose, in vacutainer tubes containing clot activator with gel separator.
Similarly, blood samples were collected for retrospective analyses on the day of the first vaccine injection from a subset of 612 MS patients and from the 63 control subjects.
To avoid time-dependent artifacts, samples were processed within two hours after blood collection, and serum was stored at -80°C until use.
Detection of anti‐SARS‐CoV‐2‐S and anti‐SARS‐CoV‐2‐N antibodies in serum samples was performed using the electrochemiluminescence immunoassays Elecsys^® Anti-SARS-CoV-S and Elecsys^® Anti-SARS-CoV-N (Roche) on the automated Cobas e-411 analyzer, according to the manufacturer’s instructions. Anti-S results are expressed as units per ml (U/ml).

Blood samples were collected in vacutainer tubes containing clot activator and gel separator.
Samples were processed within two hours after blood collection to avoid time-dependent artifacts, and subsequently serum was stored at -80°C until use. Quantification of SARS-CoV-2 antibodies direct against the proteins Spike (S) or Nucleocapsid (N) in human serum was performed using the electrochemiluminescence immunoassays Elecsys^® Anti-SARS- CoV-S and Elecsys^® Anti-SARS-CoV-N (Roche). Anti-S and Anti-N results are expressed as units per ml (U/ml). The anti-N reactive index cutoff (COI) used is > 1.